0001576280-25-000246
SEC filingGuardant Health delivered 31% YoY revenue growth in Q2 2025 driven by oncology volume and Shield screening launch, while operating losses widened slightly due to commercial expansion.
Guardant Health reported total revenue of $232.1 million for the three months ended June 30, 2025, a 31% increase compared to $177.2 million in the prior-year period. This top-line growth was primarily fueled by higher oncology test volumes and the commercial launch of the Shield blood test for colorectal cancer screening. Loss from operations widened to $106.4 million from $100.6 million in Q2 2024, as a 22% increase in total operating expenses to $338.5 million outpaced revenue growth. The operating expense increase was heavily concentrated in sales and marketing, which surged 46% to $119.6 million to support the Shield launch and broader commercial expansion. Net loss improved slightly to $99.9 million from $102.6 million, as the higher operating loss was offset by a favorable swing in other income/expense. In Q2 2024, the company recorded a $15.1 million expense primarily from unrealized losses on its Lunit, Inc. investment, whereas Q2 2025 other expense was immaterial. Interest income also declined 46% to $7.6 million due to lower investment balances and market rates.
Revenue growth was broad-based across the company's core segments. Oncology revenue, the largest segment, increased 22% to $158.7 million, driven by a 30% increase in test volume to approximately 64,000 tests and improved reimbursement for the Guardant360 CDx and Guardant360 Liquid tests. This was partially offset by a reduction in revenue related to performance obligations satisfied in prior periods. Biopharma and data revenue grew 28% to $56.0 million, reflecting higher test volume and average selling price for the GuardantINFINITY test, along with increased service agreement revenue. The most significant mix shift came from the Screening segment, which generated $14.8 million in revenue from approximately 16,000 Shield tests. This marks the first full quarter of commercial Shield availability following FDA approval and Medicare coverage in August 2024. Licensing and other revenue declined 15% to $2.6 million due to a one-time partnership payment in the prior year. Cost of revenue increased only 12% to $81.2 million, slower than revenue growth, indicating improved cost per sample for both oncology tests and the Shield screening test.
Management is focused on driving commercial adoption of the recently launched Shield blood test, which received a significant boost with its inclusion in the National Comprehensive Cancer Network (NCCN) colorectal cancer screening guidelines in June 2025. The company also received FDA Breakthrough Device designation for its Shield multi-cancer detection (MCD) test, and patient enrollment began in the NCI-funded Vanguard study. Investment in research and development is expected to continue, particularly for clinical studies like the SHIELD LUNG study and the ORACLE study for Guardant Reveal. Sales and marketing expenses are anticipated to remain elevated to support the Shield launch and international expansion. The company believes its $735.5 million in cash, cash equivalents, and restricted cash, combined with anticipated cash flows from operations, will be sufficient to meet cash requirements for more than 12 months. Key strategic priorities include expanding payer coverage, growing biopharma partnerships, and advancing the Shield platform into lung cancer screening and multi-cancer detection.
Cash and cash equivalents stood at $629.1 million with restricted cash of $106.3 million, of which $105.7 million collateralizes the TwinStrand IP litigation. Total cash equivalents and restricted cash reached $735.5 million. Short-term marketable debt securities declined to zero from $314.4 million at year-end 2024. Convertible senior notes net carrying amount was $1,115.5 million after the February 2025 exchange.
No aggregate purchase commitments are quantified in the Notes. Operating lease liabilities total $218.6 million with $16.6 million due in the remainder of 2025. The $83.4 million TwinStrand litigation liability remains recorded in other long-term liabilities pending post-trial motions.
In connection with the Note Exchange Transaction the Company repurchased $45.0 million of common stock (976,351 shares) at $46.09 per share. It issued $600.0 million 2031 Notes and retired $659.3 million 2027 Notes, recognizing a $13.7 million gain on extinguishment. No dividends were declared.
The Company operates as a single segment. Revenue is disclosed by source (Oncology $158.7 million, Biopharma and data $56.0 million, Screening $14.8 million) but no operating income or margin by segment is provided in the Notes.
Net loss of $195.1M in H1 2025 improved from $217.6M in H1 2024, but operating cash flow remained negative at -$123.0M (vs -$124.3M). The primary non-cash add-backs were stock-based compensation ($80.2M) and depreciation/amortization ($20.3M). Working capital changes consumed cash: accounts receivable increased $20.4M, inventory $13.0M, and prepaids $7.3M, partially offset by deferred revenue growth of $19.1M. Capex of $10.1M was modest relative to operating cash burn. The company generated $292.2M from investing activities, mainly from maturities of marketable debt securities ($307.3M). Financing activities used $65.2M, including $45.0M for treasury stock repurchase and $22.9M for employee taxes on RSU settlements. No free cash flow is explicitly stated; however, CFO minus capex implies -$133.1M. The company ended with $735.5M in cash, cash equivalents, and restricted cash, up from $629.8M at the start of the period.